Stryker raises dividend to $0.84 per share for Q2

PORTAGE, Michigan - Stryker Corporation (NYSE:SYK), a global leader in medical technologies with a market capitalization of $146.77 billion, has announced an increase in its quarterly dividend. The Board of Directors declared a dividend of $0.84 per share, payable on July 31, 2025, to shareholders of record as of June 30, 2025. This represents a 5.0% increase from the previous year and maintains the dividend rate from the prior quarter. According to InvestingPro data, the stock currently yields 0.87% and is trading near its 52-week high.

The company is known for its wide range of medical products and services, including those in MedSurg, Neurotechnology, and Orthopaedics. Stryker’s commitment to improving healthcare outcomes is reflected in its impact on over 150 million patients annually across the globe. The company has demonstrated strong performance with revenue growth of 10.76% and maintains a "GREAT" financial health rating according to InvestingPro analysis.

This dividend announcement is part of Stryker’s ongoing strategy to deliver value to its shareholders. The company’s consistent dividend payments underscore its financial health and commitment to returning capital to investors.

Investors and shareholders are advised that the information regarding the dividend is based on a press release statement from Stryker Corporation.

In other recent news, Stryker Corporation reported robust financial results for the first quarter of 2025, with earnings per share (EPS) of $2.84, surpassing analysts’ expectations of $2.71. The company achieved revenues of $5.9 billion, exceeding the anticipated $5.68 billion, and reported an impressive organic sales growth of 10.1%. Following these results, Stryker raised its organic sales growth forecast for fiscal year 2025 to a range of 8.5% to 9.5%, although it adjusted its EPS guidance downward to $13.20 to $13.45 due to tariff-related headwinds. UBS has increased Stryker’s stock price target to $421 from $405, maintaining a Neutral rating, while Evercore ISI lowered its target to $390 from $400, keeping an Outperform rating. The company is also in the early stages of launching new products, including the Mako Spine and Shoulder systems, with existing products like the Mako robotic system gaining traction. Despite positive indicators, Stryker faces challenges such as a $200 million tariff impact for 2025, which it plans to mitigate through pricing adjustments and operational efficiencies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.